Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence

Suzaki, Isao; Kobayashi, Hitome

doi:10.21873/invivo.12393

Cited by 9 publications

(11 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, antiviral drugs, such as remdesivir, lopinavir, and hydroxychloroquine, which have clinically prescribed for use in COVID-19 disease management, may cause liver damage. This may increase drug toxicity or aggravate the severity of SARS-CoV-2 infection [ 81 ].…”

Section: Sars-cov-2 and Gastrointestinal Systemmentioning

confidence: 99%

SARS‐CoV‐2 infection and multi-organ system damage: a review

Rabaan

Smajlović

Tombuloğlu

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

The BJBMS publishes an "Advanced online" manuscript format as a free service to authors in order to expedite the dissemination of scientific findings to the research community as soon as possible after acceptance following peer review and corresponding modification (where appropriate). An "Advanced online" manuscript is published online prior to copyediting, formatting for publication and author proofing, but is nonetheless fully citable through its Digital Object Identifier (doi®). Nevertheless, this "Advanced online" version is NOT the final version of the manuscript.

show abstract

Section: Sars-cov-2 and Gastrointestinal Systemmentioning

confidence: 99%

SARS‐CoV‐2 infection and multi-organ system damage: a review

Rabaan

Smajlović

Tombuloğlu

et al. 2022

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…Practices like face masks and handwashing appear to be mutually beneficial for management of AR and COVID‐19 3387 . Standard therapies for AR, including INCS, oral and topical antihistamines, montelukast, and AIT, were not identified as increasing susceptibility or severity of COVID‐19 infection 3363,3364,3370,3414,3421 . Systemic corticosteroids may be a concern although this is not a standard therapy for AR 3422 .…”

Section: Special Section On Covid‐19mentioning

confidence: 99%

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

115

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

“…Air pollution can potentially play a role in the susceptibility to SARS-CoV-2 infection by providing air-borne particles to transport virions and affecting the barrier and innate immunity functions of the respiratory epithelium [ 73 ]. Available evidence also suggests that the relatively common URT conditions of allergic rhinitis and chronic rhinosinusitis do not increase the risk of COVID-19 [ 74 ]. The elevated production of T H 2 cytokines, which is common in airway allergic diseases, reduces ACE2 but increases TMPRSS2 expression levels in the URT [ 75 ].…”

Section: Other Factors Influencing Susceptibility To Sars-cov-2 Infectionmentioning

confidence: 99%

Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air

Ramasamy

2021

IJMS

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as with the influenza virus, has been shown to spread more rapidly during winter. Severe coronavirus disease 2019 (COVID-19), which can follow SARS-CoV-2 infection, disproportionately affects older persons and males as well as people living in temperate zone countries with a tropical ancestry. Recent evidence on the importance of adequately warming and humidifying (conditioning) inhaled air in the nasal cavity for reducing SARS-CoV-2 infectivity in the upper respiratory tract (URT) is discussed, with particular reference to: (i) the relevance of air-borne SARS-CoV-2 transmission, (ii) the nasal epithelium as the initial site of SARS-CoV-2 infection, (iii) the roles of type 1 and 3 interferons for preventing viral infection of URT epithelial cells, (iv) weaker innate immune responses to respiratory viral infections in URT epithelial cells at suboptimal temperature and humidity, and (v) early innate immune responses in the URT for limiting and eliminating SARS-CoV-2 infections. The available data are consistent with optimal nasal air conditioning reducing SARS-CoV-2 infectivity of the URT and, as a consequence, severe COVID-19. Further studies on SARS-CoV-2 infection rates and viral loads in the nasal cavity and nasopharynx in relation to inhaled air temperature, humidity, age, gender, and genetic background are needed in this context. Face masks used for reducing air-borne virus transmission can also promote better nasal air conditioning in cold weather. Masks can, thereby, minimise SARS-CoV-2 infectivity and are particularly relevant for protecting more vulnerable persons from severe COVID-19.

show abstract

Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence

Cited by 9 publications

References 53 publications

SARS‐CoV‐2 infection and multi-organ system damage: a review

SARS‐CoV‐2 infection and multi-organ system damage: a review

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air

Contact Info

Product

Resources

About